Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass
| Autor: | A. L. Teachey, S. F. Weber, S. M. Griffin, S. M. Valanejad, Steven W. Johnson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pharmacology
Ledipasvir medicine.medical_specialty Sofosbuvir Gastric bypass surgery business.industry Hepatitis C virus Gastric bypass medicine.disease_cause Virus Surgery 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chronic hepatitis chemistry medicine LEDIPASVIR/SOFOSBUVIR 030211 gastroenterology & hepatology Pharmacology (medical) 030212 general & internal medicine business medicine.drug |
| Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 42:624-626 |
| ISSN: | 0269-4727 |
| DOI: | 10.1111/jcpt.12547 |
| Popis: | SummaryWhat is known and objective The impact of gastric bypass surgery on the pharmacokinetics of various medications has been reported. Presently, no data exist for the treatment of chronic hepatitis C virus with ledipasvir/sofosbuvir (LDV/SOF) in an individual with a history of gastric bypass. Case description We report the successful cure of an individual who was treated with LDV/SOF who had a history of gastric bypass. The patient tolerated LDV/SOF well while only experiencing a minor headache. What is new and conclusion Ledipasvir/sofosbuvir treatment may still be effective in those with a history of gastric bypass surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |